"Pfizer is pleased to gain full access to this system for antibody discovery and protein engineering."
Dr. Will Somers
VP of Global Biotherapeutic Technologies
“One of the reasons we chose Genedata Biologics was the platform’s process coverage. We required that the full diversity of Pfizer’s large-molecule processes and technologies be supported by one integrated system. Genedata Biologics’ flexibility allows Pfizer to configure the system to address both proprietary discovery processes as well as Pfizer-specific business processes and nomenclature.”
Dr. Sergio Rotstein
Director of Research Business Technology